Funding
Funding not disclosed
Founders
Product
Problem
NodCure addresses the challenge of treating infectious diseases and cancer, where current therapies may have limited efficacy or significant side effects. There is a need for innovative approaches that can enhance the body's natural defenses and restore health in a more targeted and effective manner.
Solution
NodCure is developing microbiome-based drugs and dual-target antibodies designed to modulate the immune system and directly target disease-causing agents. Their approach leverages synthetic drugs to enhance the body's natural functions, aiming to restore patient health by improving the body's ability to fight infections and cancer. The company focuses on developing next-generation therapeutics to address unmet needs in infectious disease and oncology.
Target Audience
NodCure's primary target audience includes patients suffering from infectious diseases and cancer, as well as healthcare providers seeking innovative and effective treatment options.
Features
- Microbiome-based drug development targeting infectious diseases.
- Dual-target antibody development for cancer treatment.
- Synthetic drugs designed to enhance the body's natural immune functions.
- Focus on inflammation, metabolic disorders, cancer, and bacterial/viral infections.